



Published on *Puma Biotechnology Investor Center* (<https://investor.pumabiotechnology.com>) on 5/9/17 1:20 pm PDT

Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference

Release Date:

Tuesday, May 9, 2017 1:20 pm PDT

Terms:**Dateline City:**

LOS ANGELES

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBXI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m. PDT on Tuesday, May 16, at the Bank of America Merrill Lynch 20th Annual Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.

A live webcast of the presentation will be available on the Company's website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates—PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Language:

English

Contact:

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian
+1-424-248-6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
or
Russo Partners
+1-212-845-4200
David Schull
david.schull@russopartnersllc.com
or
Amiad Finkelthal
amiad.finkelthal@russopartnersllc.com

Ticker Slug:

Ticker: PBXI

Exchange: NASDAQ

ISIN:

US74587V1070

Source URL: <https://investor.pumabiotechnology.com/press-release/puma-biotechnology-present-bank-america-merrill-lynch-2017-health-care-conference>